Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidanceSemaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance
Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) published in the journal Nature Medicine. Semaglutide or tirzepatide should be the Read More
GLP-1 Receptor Agonists and Cancer Risk in Adults With ObesityGLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity. This retrospective cohort study examines whether taking glucagon-like peptide-1 receptor agonists is associated with increased risk of different cancers among patients with obesity.
Once-Monthly GLP-1 Shot? Mangos for Blood Sugar Control; New Acromegaly TreatmentOnce-Monthly GLP-1 Shot? Mangos for Blood Sugar Control; New Acromegaly Treatment
(MedPage Today) — The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of up to 14.1% by week 28 with class-leading tolerability in a phase IIb trial, said developer Metsera… (MedPage Today) — The investigational GLP-1 receptor agonist MET-097i, which may be able Read More
Best Practices Needed for GLP-1 Drug Prescribing in Sleep Apnea, Experts SayBest Practices Needed for GLP-1 Drug Prescribing in Sleep Apnea, Experts Say
(MedPage Today) — At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA), particularly tirzepatide (Zepbound), which late last year became the first FDA-approved drug for… (MedPage Today) — At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists Read More
GLP-1 Drugs Show Benefits in Lupus Patients With DiabetesGLP-1 Drugs Show Benefits in Lupus Patients With Diabetes
(MedPage Today) — Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk of serious cardiovascular and kidney diseases when they took GLP-1 receptor agonists compared with… (MedPage Today) — Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus Read More
GLP-1 Scripts for Seniors? Expect Prior AuthorizationsGLP-1 Scripts for Seniors? Expect Prior Authorizations
(MedPage Today) — Hurdles to receive GLP-1 receptor agonists rose sharply in the last several years for Medicare Part D beneficiaries, a national study showed. Nearly all plans instituted prior authorization from 2020 to 2025, and many started… (MedPage Today) — Hurdles to receive GLP-1 receptor agonists rose sharply in the last several years Read More
Pill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggestsPill form of semaglutide may be a suitable option for adults with overweight or obesity, trial suggests
A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity. A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 Read More
GLP-1 Drugs Look Good for Psoriasis, Not So Much for HairGLP-1 Drugs Look Good for Psoriasis, Not So Much for Hair
(MedPage Today) — GLP-1 agonists appeared to have a bigger impact on the physical and mental health of patients with psoriasis compared with other patients, a large retrospective cohort study showed. Reductions in overall mortality, major adverse… (MedPage Today) — GLP-1 agonists appeared to have a bigger impact on the physical and mental health Read More
Novo Nordisk study finds greater waist reduction with higher semaglutide dosageNovo Nordisk study finds greater waist reduction with higher semaglutide dosage
A Novo Nordisk-designed trial, conducted at 68 international hospitals, specialist clinics, and medical centers with investigators from University of Texas Southwestern Medical Center and other institutions, reports greater reductions with once-weekly semaglutide 7.2 mg than placebo in bodyweight, waist circumference, and HbA1c over 72 weeks. A Novo Nordisk-designed trial, conducted at 68 international hospitals, specialist Read More
People on Ozempic who eat to regulate emotions less likely to lose weight, research revealsPeople on Ozempic who eat to regulate emotions less likely to lose weight, research reveals
GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes—helping stabilize blood glucose and lose weight, which contributes to diabetes complications. But not everyone benefits equally. GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes—helping stabilize blood glucose and lose weight, which contributes to diabetes complications. But not Read More